Defence Therapeutics Appoints Dr. Amie Phinney as Director
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney, PhD, MBA to its Board of Directors. Dr. Phinney, who recently joined as Strategy and Business Advisor, will now expand her role to help drive governance and long-term value creation.
The company has granted Dr. Phinney 100,000 stock options, exercisable at $0.75 per share for three years, vesting immediately. This appointment strengthens Defence's leadership team as it advances its drug-delivery platform development.
Defence Therapeutics (OTCQB: DTCFF), una società biotecnologica specializzata in tecnologie di rilascio di farmaci, ha nominato Dr. Amie Phinney, PhD, MBA al suo Consiglio di Amministrazione. La Dott.ssa Phinney, che recentemente si è unita come Strategy and Business Advisor, estenderà ora il suo ruolo per contribuire a governanza e creazione di valore a lungo termine.
La compagnia ha concesso alla Dott.ssa Phinney 100.000 stock option, exercibili a $0.75 per azione per tre anni, con maturazione immediata. Questa nomina rafforza il team dirigenziale di Defence mentre avanza nello sviluppo della sua piattaforma di rilascio di farmaci.
Defence Therapeutics (OTCQB: DTCFF), una empresa biotecnológica centrada en tecnologías de liberación de fármacos, ha nombrado a la Dra. Amie Phinney, PhD, MBA en su Junta Directiva. La Dra. Phinney, quien recientemente se unió como Strategy and Business Advisor, ampliará ahora su papel para ayudar a impulsar la gobernanza y la creación de valor a largo plazo.
La compañía ha otorgado a la Dra. Phinney 100,000 opciones sobre acciones, exercibles a $0.75 por acción durante tres años, con vesting inmediato. Este nombramiento fortalece al equipo de liderazgo de Defence a medida que avanza en el desarrollo de su plataforma de entrega de fármacos.
Defence Therapeutics (OTCQB: DTCFF)는 약물 전달 기술에 중점을 둔 생명공학 기업으로, Amie Phinney 박사, PhD, MBA를 이사회에 임명했습니다. Strategy and Business Advisor로 최근 합류한 Phinney 박사는 이제 거버넌스 및 장기 가치 창출을 돕기 위해 역할을 확장합니다.
회사는 Phinney 박사에게 100,000주식 옵션을 부여했으며, 주당 행사가는 $0.75로 3년 동안 행사 가능하고 즉시 가속 vesting됩니다. 이 임명은 Defence의 리더십 팀을 강화하고 약물 전달 플랫폼 개발을 가속화하는 데 기여합니다.
Defence Therapeutics (OTCQB: DTCFF), une entreprise biotechnologique spécialisée dans les technologies de délivrance de médicaments, a nommé Dr. Amie Phinney, PhD, MBA au conseil d'administration. La Dr Phinney, qui a récemment rejoint en tant que Strategy and Business Advisor, élargira désormais son rôle pour aider à promouvoir la gouvernance et la création de valeur à long terme.
La société a accordé à Dr Phinney 100 000 options sur actions, exerçables à $0,75 par action pendant trois ans, avec mise sous vesting immédiate. Cette nomination renforce l'équipe de direction de Defence alors qu'elle fait progresser le développement de sa plateforme de délivrance de médicaments.
Defence Therapeutics (OTCQB: DTCFF), ein biotechnologisches Unternehmen, das sich auf Technologien zur Arzneimittelabgabe konzentriert, hat Dr. Amie Phinney, PhD, MBA in den Vorstand berufen. Dr. Phinney, die kürzlich als Strategy and Business Advisor beigetreten ist, wird ihre Rolle nun erweitern, um Governance und langfristige Wertschöpfung voranzutreiben.
Das Unternehmen hat Dr. Phinney 100.000 Aktienoptionen gewährt, ausübbar zu 0,75 USD pro Aktie über drei Jahre, vesting sofort. Diese Berufung stärkt das Führungsteam von Defence, während das Unternehmen seine Plattformentwicklung vorantreibt.
Defence Therapeutics (OTCQB: DTCFF)، وهي شركة تكنولوجيا حيوية تركز على تقنيات توصيل الدواء، عينت الدكتورة أمي فينني، PhD، MBA في مجلس إدارتها. الدكتورة فينني، التي انضمت حديثاً كمستشارة للاستراتيجية والأعمال، ستوسع دورها الآن للمساعدة في الحوكمة وخلق قيمة طويلة الأجل.
ومنحت الشركة للدكتورة فينني 100,000 خيار أسهم، قابلة للممارسة بسعر $0.75 للسهم لمدة ثلاث سنوات، مع استحقاق فوري. تؤكد هذه التعيين قوة فريق القيادة في Defence بينما تتقدم في تطوير منصتها لتوصيل الدواء.
Defence Therapeutics (OTCQB: DTCFF)，是一家专注于药物递送技术的生物科技公司，已任命Amie Phinney博士，PhD，MBA进入董事会。 Phinney博士最近加入担任Strategy and Business Advisor，现在将扩大其角色，帮助推动公司治理和长期价值创造。
公司已授予Phinney博士100,000股股票期权，行权价为$0.75/股，有效期三年，立即归属。此任命加强了Defence的领导团队，推进其药物递送平台的发展。
- Strategic addition of experienced leader with global pharma and biotech expertise
- Immediate vesting of stock options aligns new director's interests with shareholders
- Stock option grant at $0.75 represents potential dilution for existing shareholders
Montreal, Quebec--(Newsfile Corp. - September 16, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA to its Board of Directors, effective immediately.
Dr. Phinney recently joined Defence as a Strategy and Business Advisor, working closely with leadership to refine the Company's direction. We are thrilled to now expand her role to the Board of Directors, where she will help drive governance and long-term value creation as Defence accelerates the advancement of its innovative drug-delivery platform.
"Amie has already made a strong impact in shaping our strategic priorities," said Sébastien Plouffe, Founder and CEO of Defence Therapeutics. "Her experience spanning global pharma, biotech ventures, and commercialization will be invaluable as we continue building momentum."
"I am honoured to join the Board at this exciting stage," said Dr. Phinney. "Defence's science has the potential to be transformative, and I look forward to supporting the Company's growth and long-term success."
With Dr. Phinney's appointment, Defence strengthens its leadership team and Board as it enters a pivotal phase of translating breakthrough drug-delivery science that has the potential to reshape the treatment landscape and deliver meaningful value for patients and shareholders alike.
The Company has granted 100,000 incentive stock options to Dr. Phinney (the "Options"), in accordance with the terms and conditions of Defence's Omnibus Incentive Plan. The Options are vested immediately and exercisable at a price of
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/266539
FAQ
Who is Dr. Amie Phinney and what is her new role at Defence Therapeutics (DTCFF)?
What stock options were granted to Dr. Phinney by Defence Therapeutics?
How will Dr. Phinney's appointment benefit Defence Therapeutics (DTCFF)?
What is Defence Therapeutics' main business focus?
